- Home
- IREN vs ROIV Comparison
IREN vs ROIV Comparison
Compare IREN & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IREN | ROIV |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | Australia | United Kingdom |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.3B | 23.2B |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | IREN | ROIV |
|---|---|---|
| Price | $41.36 | $34.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 9 |
| Target Price | ★ $62.50 | $28.94 |
| AVG Volume (30 Days) | ★ 32.4M | 5.9M |
| Earning Date | 05-07-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 234.48 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $501,023,000.00 | $8,260,000.00 |
| Revenue This Year | $104.58 | N/A |
| Revenue Next Year | $200.20 | $744.61 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 167.65 | N/A |
| 52 Week Low | $14.72 | $10.90 |
| 52 Week High | $76.87 | $37.00 |
Technical Indicators
Market Signals| Indicator | IREN | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 45.25 | 57.98 |
| Support Level | $38.09 | $26.65 |
| Resistance Level | $46.11 | $37.00 |
| Average True Range (ATR) | 3.45 | 1.07 |
| MACD | 0.39 | -0.28 |
| Stochastic Oscillator | 69.11 | 40.00 |
Price Performance
Historical ComparisonAbout IREN Iris Energy Limited
IREN owns data centers powered by renewable energy in Canada and the US for bitcoin mining and AI cloud infrastructure. The company is in the process of converting its existing bitcoin capacity for AI purposes and securing new power and land supply to expand its data center operation. IREN works closely with industry leaders in AI, such as Microsoft, to support their cloud infrastructure ambitions.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.